2018
Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy.
Leapman M, Nguyen H, Cowan J, Xue L, Stohr B, Simko J, Cooperberg M, Carroll P. Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy. Journal Of Clinical Oncology 2018, 36: 118-118. DOI: 10.1200/jco.2018.36.6_suppl.118.Peer-Reviewed Original ResearchPCa-specific mortalityRadical prostatectomyBiochemical recurrenceCCP scoreIHC panelCell cycle progression scoreExpression statusERG expressionCox proportional hazards regressionRisk of BCRPositive ERG expressionProportional hazards regressionProstate cancer riskPrediction of outcomeHigh Ki67Median ageIndependent predictorsPathologic characteristicsHazards regressionPrognostic utilityIHC statusInstitutional databaseLocalized PCaC-indexImmunohistochemistry panel
2016
Relationship of phosphodiesterase type 5 inhibitor to biochemical recurrence after definitive therapy for prostate cancer.
Leapman M, Cowan J, Nguyen H, Porten S, Cooperberg M, Carroll P. Relationship of phosphodiesterase type 5 inhibitor to biochemical recurrence after definitive therapy for prostate cancer. Journal Of Clinical Oncology 2016, 34: 119-119. DOI: 10.1200/jco.2016.34.2_suppl.119.Peer-Reviewed Original ResearchPhosphodiesterase type 5 inhibitorsBiochemical recurrenceType 5 inhibitorsProstate cancerUse of PDE5iMedian age 61 yearsMedian age 69 yearsProstate Strategic Urologic Research EndeavorRisk of BCRCox proportional hazards modelAndrogen deprivation therapyAge 61 yearsAge 69 yearsKaplan-Meier methodSexual function scoresCohort of menProportional hazards modelDeprivation therapyPrescription complianceDefinitive therapyTime-dependent useDefinitive treatmentDisease recurrenceClinical evidenceBaseline use